Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
Plasma Exchange for Anti-GBM Disease With Dialysis Dependency: A Case Series on Clinical Outcomes and Safety.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sakuragi Minoru, Miyauchi Miho, Kubo Misaki, Aso Mea, Ogura Sanae, Sokai Yuko, Tsuji Yoshiki, Mori Keita P, Torikoshi Kazuo, Suzuki Hiroyuki, Komiya Toshiyuki, Muso Eri, Endo Tomomi, Matsubara Takeshi, Tsukamoto Tatsuo
Аннотация
INTRODUCTION: The efficacy of plasma exchange (PEx) in patients with anti-glomerular basement membrane antibody (anti-GBM Ab) disease requiring renal replacement therapy (RRT) at diagnosis remains unclear. This study aimed to investigate the outcomes and safety of patients with uremic anti-GBM Ab disease undergoing PEx.
METHODS: We retrospectively analyzed nine patients confirmed by renal biopsy who received PEx using fresh frozen plasma or 5% human albumin solution and underwent hemodialysis (HD) concomitantly with standard immunosuppressive therapy. The outcome was determined as dialysis dependency, and safety was evaluated for adverse events.
RESULTS: Two patients (22.2%) achieved dialysis independence at 10 and 11 months. Both patients had relatively preserved normal glomeruli (15.8%-37.2%) and achieved early remission. Retroperitoneal hemorrhage and recalcitrant anti-GBM Ab were noteworthy in other cases.
CONCLUSION: PEx can facilitate renal recovery in selected patients with anti-GBM disease requiring RRT. Pathological evaluation may be useful to determine the intensity and duration of treatment, including PEx.
METHODS: We retrospectively analyzed nine patients confirmed by renal biopsy who received PEx using fresh frozen plasma or 5% human albumin solution and underwent hemodialysis (HD) concomitantly with standard immunosuppressive therapy. The outcome was determined as dialysis dependency, and safety was evaluated for adverse events.
RESULTS: Two patients (22.2%) achieved dialysis independence at 10 and 11 months. Both patients had relatively preserved normal glomeruli (15.8%-37.2%) and achieved early remission. Retroperitoneal hemorrhage and recalcitrant anti-GBM Ab were noteworthy in other cases.
CONCLUSION: PEx can facilitate renal recovery in selected patients with anti-GBM disease requiring RRT. Pathological evaluation may be useful to determine the intensity and duration of treatment, including PEx.